< Back to all clusters
[HEALTH] · Canada, Congo - Kinshasa · 53 sources

started · updated

Moderna's Bundibugyo Ebola Vaccine Enters Phase 1 Trial in Canada

Health Canada has authorized Moderna to begin a Phase 1 clinical trial of its mRNA‑1469 vaccine targeting the Bundibugyo strain of Ebola. The first participant was dosed on 3 August at a site in Truro, Nova Scotia, with the trial also taking place in Halifax and Toronto and enrolling about 80 healthy adult volunteers. The study will assess safety, tolerability and the immune response generated by the vaccine.

The trial is supported by the Coalition for Epidemic Preparedness Innovations (CEPI), which has pledged up to $50 million for pre‑clinical work, the Phase 1 study and manufacturing of additional doses. The effort responds to the ongoing outbreak in the Democratic Republic of the Congo, where the World Health Organization and Africa CDC have declared a public‑health emergency. As of 1 August, the outbreak has produced roughly 3,748 confirmed cases and 1,657 deaths.

Moderna has said that, if the vaccine is licensed, it will make at least 500,000 doses available to low‑ and middle‑income countries under access‑pricing terms.

Entities

Bundibugyo ebolavirus · Coalition for Epidemic Preparedness Innovations · Coalition for Epidemic Preparedness Innovations (CEPI) · Democratic Republic of Congo · Democratic Republic of the Congo · Hamilton Bennett · Health Canada · Moderna · Moderna Inc. · mRNA-1469 · mRNA‑1469 · mRNA‑1469 (Bundibugyo Ebola vaccine)

Claims

What the coverage asserts, and how many sources carry each claim.

Sources

about 1 month ago
about 1 month ago
about 2 months ago
about 1 month ago
about 2 months ago
about 1 month ago
about 2 months ago